References
- Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017 Sep 16;390(10100):1211–1259.
- Hyman SE. Revolution stalled. Sci Transl Med. 2012 Oct 10;4(155):155cm11.
- Psychiatric Genomics Consortium. [cited 2019 Sep 3]. Available from: https://www.med.unc.edu/pgc/about-us/
- Sullivan PF, Agrawal A, Bulik CM, et al. Psychiatric genomics: an update and an Agenda. Am J Psychiatry. 2018 Jan 1;175(1):15–27.
- PsychENCODE Consortium. [cited 2019 Sep 3]. Available from: http://www.psychencode.org
- PsychENCODE. Revealing the brain’s molecular architecture. Science. 2018 Dec 14;362(6420):1262–1263.
- U. S. Food and Drug Administration. Guidance for industry and FDA staff. qualification process of drug development tools. 2014. [cited 2019 May 20]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-process-drug-development-tools
- U.S. Food and Drug Administration. Guidance for indutry. Expedited programs for serious conditions—drugs and biologics. 2017. [cited 2019 May 20]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics
- U. S. Food and Drug Administration. Draft guidance for industry and FDA staff. Biomarker qualification: evidentiary framework. 2018. [cited 2019 May 20]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biomarker-qualification-evidentiary-framework
- U. S. Food and Drug Administration. Draft guidance. Major depressive disorder: developing drugs for treatment. 2018. [cited 2019 May 20]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/major-depressive-disorder-developing-drugs-treatment
- Mullard A. 2018 FDA drug approvals. Nat Rev Drug Discov. 2019 Feb;18(2):85–89.
- Alzheimer’s Disease Neuroimaging Initiative. [cited 2019 Sep 3]. Available from: http://adni.loni.usc.edu
- Veitch DP, Weiner MW, Aisen PS, et al. Understanding disease progression and improving Alzheimer’s disease clinical trials: recent highlights from the Alzheimer’s disease neuroimaging initiative. Alzheimers Dement. 2019 Jan;15(1):106–152.
- Autism Biomarkers Consortium. [cited 2019 Sep 3]. Available from: https://fnih.org/what-we-do/biomarkers-consortium/programs/autism-biomarkers
- Grabb MC, Cross AJ, Potter WZ, et al. Derisking psychiatric drug development: the NIMH’s fast fail program, a novel precompetitive model. J Clin Psychopharmacol. 2016 Oct;36(5):419–421.
- Krystal AD, Pizzagalli DA, Mathew SJ, et al. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nat Rev Drug Discov. 2019 Jan;18(1):82–84.
- North American Prodromal Longitudinal Study. [cited 2019 Sep 3]. Available from: http://campuspress.yale.edu/napls/
- Philadelphia Neurodevelopmental Cohort. [cited 2019 Sep 3]. Available from: https://www.med.upenn.edu/bbl/philadelphianeurodevelopmentalcohort.html
- PRONIA. [cited 2019 Sep 3]. Available from: https://www.pronia.eu/
- PSYSCAN. [cited 2019 Sep 3]. Available from: http://psyscan.eu/
- Chung Y, Addington J, Bearden CE, et al. Use of machine learning to determine deviance in neuroanatomical maturity associated with future psychosis in youths at clinically high risk. JAMA Psychiatry. 2018 Sep 1;75(9):960–968.
- Koutsouleris N, Kambeitz-Ilankovic L, Ruhrmann S, et al. Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recent-onset depression: a multimodal, multisite machine learning analysis. JAMA Psychiatry. 2018 Sep 26;75:1156.
- Accelerating Medicines Partnership. [cited 2019 Sep 3]. Available from: https://www.nih.gov/research-training/accelerating-medicines-partnership-amp
- Advancing Discovery Summit. [cited 2019 Sep 3]. Available from: https://www.nami.org/Learn-More/Research/Advancing-Discovery-Summit-Series
- Hyman SE. Revitalizing psychiatric therapeutics. Neuropsychopharmacology. 2014 Jan;39(1):220–229.